Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 1/20 | 0.58 |
| ▸ | MRGPRX4 | Q96LA9 | 7/20 | 0.57 |
| ▸ | PTGER1 | P34995 | 2/20 | 0.56 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.56 |
| ▸ | HPGD | P15428 | 3/20 | 0.54 |
| ▸ | RXRA | P19793 | 1/20 | 0.54 |
| ▸ | RXRB | P28702 | 1/20 | 0.54 |
| ▸ | NPC1 | O15118 | 2/20 | 0.54 |
| ▸ | RAB9A | P51151 | 2/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | MITF | O75030 | 1/20 | 0.54 |
| ▸ | TP53 | P04637 | 1/20 | 0.54 |
| ▸ | XBP1 | P17861 | 1/20 | 0.54 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.54 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | RELA | Q04206 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7797930 | 0.91 | MRGPRX4 (0.61) | FOLH1MRGPRX4PTGER1MCL1HPGD | |
| SCHEMBL21327232 | 0.91 | MRGPRX4 (0.61) | FOLH1MRGPRX4PTGER1MCL1HPGD | |
| SCHEMBL2469286 | 0.89 | MRGPRX4 (0.52) | FOLH1MRGPRX4PTGER1MCL1HPGD | |
| SCHEMBL4472145 | 0.88 | MRGPRX4 (0.49) | FOLH1MRGPRX4PTGER1MCL1HPGD | |
| SCHEMBL21662634 | 0.88 | KDM4A (0.52) | FOLH1MRGPRX4PTGER1MCL1HPGD | |
| SCHEMBL384030 | 0.88 | MAOB (0.57) | MRGPRX4PTGER1MCL1HPGDRXRA | |
| SCHEMBL24983867 | 0.87 | FOLH1 (0.65) | FOLH1PTGER1MCL1MEN1KMT2A | |
| SCHEMBL30892473 | 0.87 | FOLH1 (0.65) | FOLH1PTGER1MCL1MEN1KMT2A | |
| SCHEMBL10089235 | 0.87 | FOLH1 (0.69) | FOLH1PTGER1MCL1MEN1KMT2A | |
| SCHEMBL9550355 | 0.87 | FOLH1 (0.55) | FOLH1MRGPRX4PTGER1MCL1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 81 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116751200-A | Tricyclic compounds containing substituted pyridones and methods of using the same | 爱彼特生物制药公司 | 2023-09-15 | — | — | CN | disclosed |
| CN-110114071-B | Tricyclic compounds containing substituted pyridones and methods of using the same | 爱彼特生物制药公司 | 2023-07-04 | — | — | CN | disclosed |
| EP-3534903-B1 | SUBSTITUTED PYRIDINONE-CONTAINING TRICYCLIC COMPOUNDS, AND METHODS USING SAME | ARBUTUS BIOPHARMA CORP (CA) | 2022-08-03 | — | — | EP | disclosed |
| US-11013726-B2 | Substituted pyridinone-containing trycyclic compounds, and methods using same | ARBUTUS BIOPHARMA CORPORATION (CA) | 2021-05-25 | — | — | US | disclosed |
| US-11013726-B2 | Substituted pyridinone-containing trycyclic compounds, and methods using same | ARBUTUS BIOPHARMA CORPORATION (CA) | 2021-05-25 | — | — | US | disclosed |
| US-10821103-B2 | Substituted pyridinone-containing trycyclic compounds, and methods using same | ARBUTUS BIOPHARMA CORPORATION (CA) | 2020-11-03 | — | — | US | disclosed |
| US-10821103-B2 | Substituted pyridinone-containing trycyclic compounds, and methods using same | ARBUTUS BIOPHARMA CORPORATION (CA) | 2020-11-03 | — | — | US | disclosed |
| US-20200261432-A1 | SUBSTITUTED PYRIDINONE-CONTAINING TRYCYCLIC COMPOUNDS, AND METHODS USING SAME | ARBUTUS BIOPHARMA CORPORATION (CA) | 2020-08-20 | — | — | US | disclosed |
| US-20200261432-A1 | SUBSTITUTED PYRIDINONE-CONTAINING TRYCYCLIC COMPOUNDS, AND METHODS USING SAME | ARBUTUS BIOPHARMA CORPORATION (CA) | 2020-08-20 | — | — | US | disclosed |
| US-20190314347-A1 | SUBSTITUTED PYRIDINONE-CONTAINING TRYCYCLIC COMPOUNDS, AND METHODS USING SAME | ARBUTUS BIOPHARMA, INC. | 2019-10-17 | — | — | US | disclosed |
| EP-1883402-A2 | HYDROXYBENZAMIDE DERIVATIVES AND THEIR USE AS INHIBITORS OF HSP90 | Astex Therapeutics Limited (GB) | 2008-02-06 | — | — | EP | disclosed |
| EP-1877379-A1 | HYDROXYBENZAMIDE DERIVATIVES AND THEIR USE AS INHIBITORS OF HSP90 | Astex Therapeutics Limited (GB) | 2008-01-16 | — | — | EP | disclosed |
| US-20070276026-A1 | Hydroxybenzamide Derivatives And Their Use As Inhibitors Of HSP90 | ASTEX THERAPEUTICS LIMITED (GB) | 2007-11-29 | — | — | US | disclosed |
| US-20070276026-A1 | Hydroxybenzamide Derivatives And Their Use As Inhibitors Of HSP90 | ASTEX THERAPEUTICS LIMITED (GB) | 2007-11-29 | — | — | US | disclosed |
| US-20070259886-A1 | (2,4-Dihydroxy-5-isopropyl-phenyl)-[5-(2-dimethylamino-ethoxy)-1,3-dihydro-isoindol-2-yl]-methanone; inhibits or modulates activity of heat shock protein Hsp90; useful for treating cancer, particularly hematopoietic tumors of lymphoid or myeloid lineage, prostate, lung, breast cancer, melanoma | ASTEX THERAPEUTICS, LTD. (GB) | 2007-11-08 | — | — | US | disclosed |
| US-20070259886-A1 | (2,4-Dihydroxy-5-isopropyl-phenyl)-[5-(2-dimethylamino-ethoxy)-1,3-dihydro-isoindol-2-yl]-methanone; inhibits or modulates activity of heat shock protein Hsp90; useful for treating cancer, particularly hematopoietic tumors of lymphoid or myeloid lineage, prostate, lung, breast cancer, melanoma | ASTEX THERAPEUTICS, LTD. (GB) | 2007-11-08 | — | — | US | disclosed |
| US-20070259871-A1 | Hydroxybenzamide Derivatives And Their Use As Inhibitors Of HSP90 | ASTEX THERAPEUTICS LIMITED (GB) | 2007-11-08 | — | — | US | disclosed |
| US-20070259871-A1 | Hydroxybenzamide Derivatives And Their Use As Inhibitors Of HSP90 | ASTEX THERAPEUTICS LIMITED (GB) | 2007-11-08 | — | — | US | disclosed |
| WO-2006109075-A2 | HYDROXYBENZAMIDE DERIVATIVES AND THEIR USE AS INHIBITORS OF HSP90 | ASTEX THERAPEUTICS LIMITED (GB) | 2006-10-19 | — | — | WO | disclosed |
| WO-2006109085-A1 | HYDROXYBENZAMIDE DERIVATIVES AND THEIR USE AS INHIBITORS OF HSP90 | ASTEX THERAPEUTICS LIMITED (GB) | 2006-10-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070276026-A1 | Hydroxybenzamide Derivatives And Their Use As Inhibitors Of HSP90 | HSP90AB1, HSP90AB2P, HSP90AA1 | FOLH1 4750/4885MRGPRX4 2487/4885PTGER1 1835/4885 |
| US-20070259886-A1 | (2,4-Dihydroxy-5-isopropyl-phenyl)-[5-(2-dimethylamino-ethoxy)-1,3-dihydro-isoindol-2-yl]-methanone; inhibits or modulates activity of heat shock protein Hsp90; useful for treating cancer, particularly hematopoietic tumors of lymphoid or myeloid lineage, prostate, lung, breast cancer, melanoma | HSP90AB2P, HSP90AA1, HSP90AB1 | FOLH1 4191/4885MRGPRX4 1997/4885PTGER1 709/4885 |
| US-20200261432-A1 | SUBSTITUTED PYRIDINONE-CONTAINING TRYCYCLIC COMPOUNDS, AND METHODS USING SAME | HAVCR2, HCCS, TYMP | FOLH1 1071/4885MRGPRX4 3248/4885PTGER1 1582/4885 |
| US-20070259871-A1 | Hydroxybenzamide Derivatives And Their Use As Inhibitors Of HSP90 | HSP90AB1, HSP90AB2P, HSP90AA1 | FOLH1 4751/4885MRGPRX4 2480/4885PTGER1 1834/4885 |
| US-20190314347-A1 | SUBSTITUTED PYRIDINONE-CONTAINING TRYCYCLIC COMPOUNDS, AND METHODS USING SAME | HAVCR2, HCCS, TYMP | FOLH1 1071/4885MRGPRX4 3248/4885PTGER1 1582/4885 |
| US-11013726-B2 | Substituted pyridinone-containing trycyclic compounds, and methods using same | HAVCR2, HCCS, TYMP | FOLH1 1071/4885MRGPRX4 3248/4885PTGER1 1582/4885 |
| US-10821103-B2 | Substituted pyridinone-containing trycyclic compounds, and methods using same | HAVCR2, HCCS, TYMP | FOLH1 1071/4885MRGPRX4 3248/4885PTGER1 1582/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.